Search results

Found 6,298 pages
AUTHOR: Selina McKee

Your search yielded no results

  • Check if your spelling is correct.
  • Remove quotes around phrases to search for each word individually. bike shed will often show more results than "bike shed".
  • Consider loosening your query with OR. bike OR shed will often show more results than bike shed.

Affimed shares plunge on trial death

Shares in German biopharma Affimed dropped near 30% after the company said it was placing a key Phase I programme of its experimental cancer immunotherapy on hold because of serious side effects observed in trials, including a patient death. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/affimed_shares_plunge_on_trial_death_1255143

Janssen files nasal spray for depression

Janssen has submitted a marketing application to the European Medicines Agency (EMA) seeking approval of investigational nasal spray esketamine for the treatment of major depressive disorder. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/janssen_files_nasal_spray_for_depression_1255351

New competition celebrates excellence in medical information

Medical information professionals are being invited to test their mettle at this year’s inaugural PharmaTimes Medical & Scientific Excellence Awards, established to showcase and reward excellence in the field. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/new_competition_celebrates_excellence_in_medical_information_1255524

EU validates Repligen’s marketing application for fostamatinib

European regulators have validated Rigel Pharmaceuticals’ application to market fostamatinib for adult chronic immune thrombocytopenia (ITP). - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/eu_validates_repligens_marketing_application_for_fostamatinib_1255515

Carrick licenses targeted ovarian cancer drug from BTG

Dublin, Ireland-based biopharma Carrick Therapeutics has licensed exclusive globl rights to develop and commercialise BTG’s targeted ovarian cancer drug BTG945. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/carrick_licenses_targeted_ovarian_cancer_drug_from_btg_1255359

Diurnal shares plummet on trial failure

Shares in UK speciality pharma Diurnal plummeted more than 50 percent on news that a late-stage study of an experimental treatment for congenital adrenal hyperplasia (CAH) failed to meet its primary objective. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/diurnal_shares_plummet_on_trial_failure_1255142

Novartis crizanlizumab shows promise in sickle cell anaemia

A new analysis has shown that Novartis’ crizanlizumab reduced the number of patients with sickle cell disease experiencing a pain crisis. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/novartis_crizanlizumab_shows_promise_in_sickle_cell_anaemia_1255147

Mixed data for Xencor’s SLE drug

Xencor’s experimental systemic lupus erythematosus (SLE) drug XmAb5871 has failed to hit its key target in a mid-stage study. - News - PharmaTimes

by Selina McKee

www.pharmatimes.com/news/mixed_data_for_xencors_sle_drug_1254967

Latest jobs

View all

What job are you looking for?

This field is required.

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download